iShares Global Clean Energy ETF vs uniQure N.V. Ordinary Shares — how do they compare? iShares Global Clean Energy ETF trades at $16.43 (market cap $2.13B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: iShares Global Clean Energy ETF is the larger of the two by market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 88 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ICLN | QURE | |
|---|---|---|
Market Cap | $2.13B | $1.45B |
Volume | 5,190,061 | 3,323,243 |
52-Week High | $23.75 | $70.59 |
52-Week Low | $16.00 | $9.03 |
Typical Hold Time | 88 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.18 with a slight 0.35% daily gain, though technical indicators signal bearish momentum with 15 sell signals versus 1 buy. The ETF faces headwinds from higher expense ratios and volatility compared to traditional energy peers, with recent news highlighting underperformance against fossil fuel ETFs. Support and resistance cluster tightly around $17, indicating potential consolidation.
Outlook remains cautious due to weak technicals and competitive pressure from lower-cost energy ETFs. Long-term growth hinges on renewable energy adoption, but near-term risks include fee disadvantages and sector volatility. Investors should weigh clean energy exposure against more stable traditional energy alternatives.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →